{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:28:01Z","timestamp":1789122481386,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01339-0","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T21:02:09Z","timestamp":1753995729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9551-4893","authenticated-orcid":false,"given":"Harinder","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier Cheng-Hong","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5522-8852","authenticated-orcid":false,"given":"Vivian W. K.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garret M. K.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-0655","authenticated-orcid":false,"given":"Melissa","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsz-Shing","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha","family":"Raghupathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-8918","authenticated-orcid":false,"given":"Lester","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony K. Y.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Y. Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-8335","authenticated-orcid":false,"given":"Wee-Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-5593","authenticated-orcid":false,"given":"Hwei-Fang","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-4845","authenticated-orcid":false,"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8156-6978","authenticated-orcid":false,"given":"Yok-Lam","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"1339_CR1","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"1339_CR2","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1182\/blood.2023020081","volume":"142","author":"AE DeZern","year":"2023","unstructured":"DeZern AE, Greenberg PL. The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes. Blood. 2023;142:2258\u201367.","journal-title":"Blood"},{"key":"1339_CR3","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.20.02810","volume":"39","author":"A Nazha","year":"2021","unstructured":"Nazha A, Komrokji R, Meggendorfer M, Jia X, Radakovich N, Shreve J, et al. Personalized prediction model to risk stratify patients with myelodysplastic syndromes. J Clin Oncol. 2021;39:3737\u201346.","journal-title":"J Clin Oncol"},{"key":"1339_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:EVIDoa2200008.","journal-title":"NEJM Evid"},{"key":"1339_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40164-022-00328-4","volume":"11","author":"J Wu","year":"2022","unstructured":"Wu J, Zhang Y, Qin T, Xu Z, Qu S, Pan L, et al. IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons\u2265 60 years with myelodysplastic syndromes. Exp Hematol Oncol. 2022;11:73.","journal-title":"Exp Hematol Oncol"},{"key":"1339_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00894-8","volume":"13","author":"W-H Lee","year":"2023","unstructured":"Lee W-H, Tsai M-T, Tsai C-H, Tien F-M, Lo M-Y, Tseng M-H, et al. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification. Blood Cancer J. 2023;13:120.","journal-title":"Blood Cancer J"},{"key":"1339_CR7","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood.2022018896","volume":"141","author":"T Kewan","year":"2023","unstructured":"Kewan T, Bahaj W, Durmaz A, Aly M, Ogbue OD, Carraway HE, et al. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes. Blood. 2023;141:1768\u201372.","journal-title":"Blood"},{"key":"1339_CR8","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1200\/JCO.22.01784","volume":"41","author":"E Sauta","year":"2023","unstructured":"Sauta E, Robin M, Bersanelli M, Travaglino E, Meggendorfer M, Zhao L-P, et al. Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes. J Clin Oncol. 2023;41:2827\u201342.","journal-title":"J Clin Oncol"},{"key":"1339_CR9","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/JCO.20.01659","volume":"39","author":"M Bersanelli","year":"2021","unstructured":"Bersanelli M, Travaglino E, Meggendorfer M, Matteuzzi T, Sala C, Mosca E, et al. Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes. J Clin Oncol. 2021;39:1223\u201333.","journal-title":"J Clin Oncol"},{"key":"1339_CR10","doi-asserted-by":"publisher","unstructured":"Benjamin D, Sato T, Cibulskis K, Getz G, Stewart C, Lichtenstein L. Calling somatic SNVs and indels with mutect2. bioRxiv. 2019. https:\/\/doi.org\/10.1101\/861054.","DOI":"10.1101\/861054"},{"key":"1339_CR11","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/gim.2017.210","volume":"20","author":"SV Tavtigian","year":"2018","unstructured":"Tavtigian SV, Greenblatt MS, Harrison SM, Nussbaum RL, Prabhu SA, Boucher KM, et al. Modeling the ACMG\/AMP variant classification guidelines as a Bayesian classification framework. Genet Med. 2018;20:1054\u201360.","journal-title":"Genet Med"},{"key":"1339_CR12","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment\/map format and SAMtools. Bioinformatics. 2009;25:2078\u20139.","journal-title":"Bioinformatics"},{"key":"1339_CR13","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1093\/bioinformatics\/btp394","volume":"25","author":"K Ye","year":"2009","unstructured":"Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics. 2009;25:2865\u201371.","journal-title":"Bioinformatics"},{"key":"1339_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani P, Platts A, Wang Le L, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. 2012;6:80\u201392.","journal-title":"Fly"},{"key":"1339_CR15","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.","journal-title":"Nucleic Acids Res"},{"key":"1339_CR16","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Ossa JEA, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:EVIDoa2200008.","journal-title":"NEJM Evid"},{"key":"1339_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa2024534","volume":"384","author":"EJ Duncavage","year":"2021","unstructured":"Duncavage EJ, Schroeder MC, O\u2019Laughlin M, Wilson R, MacMillan S, Bohannon A, et al. Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. New Engl J Med. 2021;384:924\u201335.","journal-title":"New Engl J Med"},{"key":"1339_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000181","volume":"3","author":"A Hinai","year":"2019","unstructured":"Hinai A, Pratcorona M, Grob T, Kavelaars FG, Bussaglia E, Sanders MA, et al. The landscape of KMT2A-PTD AML: concurrent mutations, gene expression signatures, and clinical outcome. Hemasphere. 2019;3:e181.","journal-title":"Hemasphere"},{"key":"1339_CR19","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.jmoldx.2021.07.019","volume":"23","author":"B Dai","year":"2021","unstructured":"Dai B, Yu H, Ma T, Lei Y, Wang J, Zhang Y, et al. The application of targeted RNA sequencing for KMT2A-partial tandem duplication identification and integrated analysis of molecular characterization in acute myeloid leukemia. J Mol Diagn. 2021;23:1478\u201390.","journal-title":"J Mol Diagn"},{"key":"1339_CR20","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1182\/blood.2020010603","volume":"138","author":"H Awada","year":"2021","unstructured":"Awada H, Durmaz A, Gurnari C, Kishtagari A, Meggendorfer M, Kerr CM, et al. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. Blood. 2021;138:1885\u201395.","journal-title":"Blood"},{"key":"1339_CR21","first-page":"1","volume":"25","author":"E Sorrentino","year":"2021","unstructured":"Sorrentino E, Cristofoli F, Modena C, Paolacci S, Bertelli M, Marceddu G. Integration of VarSome API in an existing bioinformatic pipeline for automated ACMG interpretation of clinical variants. Eur Rev Med Pharm Sci. 2021;25:1\u20136.","journal-title":"Eur Rev Med Pharm Sci"},{"key":"1339_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100155","volume":"6","author":"M Gallo","year":"2021","unstructured":"Gallo M, Adinolfi V, Morviducci L, Acquati S, Tuveri E, Ferrari P, et al. Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)\/Associazione Medici Diabetologi (AMD)\/Societa Italiana Endocrinologia (SIE)\/Societa Italiana Farmacologia (SIF) multidisciplinary consensus position paper. ESMO Open. 2021;6:100155.","journal-title":"ESMO Open"},{"key":"1339_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/978-1-0716-2293-3_19","volume":"2493","author":"P Cingolani","year":"2022","unstructured":"Cingolani P. Variant annotation and functional prediction: SnpEff. Methods Mol Biol. 2022;2493:289\u2013314.","journal-title":"Methods Mol Biol"},{"key":"1339_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05995-x","volume":"23","author":"W Wang","year":"2025","unstructured":"Wang W, Zhang Y, Yang W, Liu X, Jiang L, Lang W, et al. The molecular prognostic scoring system for normal karyotype myelodysplastic syndromes. J Transl Med. 2025;23:76.","journal-title":"J Transl Med"},{"key":"1339_CR25","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/leu.2015.55","volume":"29","author":"MG Della Porta","year":"2015","unstructured":"Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015;29:1502\u201313.","journal-title":"Leukemia"},{"key":"1339_CR26","first-page":"1049","volume":"133","author":"S Ogawa","year":"2019","unstructured":"Ogawa S. Genetics of MDS. Blood, J Am Soc Hematol. 2019;133:1049\u201359.","journal-title":"Blood, J Am Soc Hematol"},{"key":"1339_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/0165-4608(94)90031-0","volume":"74","author":"B Johansson","year":"1994","unstructured":"Johansson B, Billstr\u00f6m R, Mauritzson N, Mitelman F. Trisomy 19 as the sole chromosomal anomaly in hematologic neoplasms. Cancer Genet Cytogenet. 1994;74:62\u20135.","journal-title":"Cancer Genet Cytogenet"},{"key":"1339_CR28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/gcc.22854","volume":"59","author":"A Tirosh","year":"2020","unstructured":"Tirosh A, Jin DX, De Marco L, Laitman Y, Friedman E. Activating genomic alterations in the Gs alpha gene (GNAS) in 274 694 tumors. Genes Chromosomes Cancer. 2020;59:503\u201316.","journal-title":"Genes Chromosomes Cancer"},{"key":"1339_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.100965","volume":"49","author":"S He","year":"2024","unstructured":"He S, Li Y, Wang L, Li Y, Xu L, Cai D, et al. DNA methylation landscape reveals GNAS as a decitabine-responsive marker in patients with acute myeloid leukemia. Neoplasia. 2024;49:100965.","journal-title":"Neoplasia"},{"key":"1339_CR30","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/2159-8290.CD-21-0508","volume":"12","author":"EC Wheeler","year":"2022","unstructured":"Wheeler EC, Vora S, Mayer D, Kotini AG, Olszewska M, Park SS, et al. Integrative RNA-omics discovers GNAS alternative splicing as a phenotypic driver of splicing factor\u2013mutant neoplasms. Cancer Discov. 2022;12:836\u201355.","journal-title":"Cancer Discov"},{"key":"1339_CR31","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41375-020-0889-7","volume":"35","author":"A Buradkar","year":"2021","unstructured":"Buradkar A, Bezerra E, Coltro G, Lasho TL, Finke CM, Gangat N, et al. Landscape of RAS pathway mutations in patients with myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. Leukemia. 2021;35:644\u20139.","journal-title":"Leukemia"},{"key":"1339_CR32","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1038\/leu.2013.160","volume":"27","author":"DM Murphy","year":"2013","unstructured":"Murphy DM, Bejar R, Stevenson K, Neuberg D, Shi Y, Cubrich C, et al. NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. Leukemia. 2013;27:2077\u201381.","journal-title":"Leukemia"},{"key":"1339_CR33","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41375-020-0920-z","volume":"35","author":"M Alfayez","year":"2021","unstructured":"Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, et al. The clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021;35:691\u2013700.","journal-title":"Leukemia"},{"key":"1339_CR34","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1182\/bloodadvances.2019000090","volume":"3","author":"SS Patel","year":"2019","unstructured":"Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, et al. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Adv. 2019;3:1540\u20135.","journal-title":"Blood Adv"},{"key":"1339_CR35","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/leu.2015.211","volume":"30","author":"CD DiNardo","year":"2016","unstructured":"DiNardo CD, Jabbour E, Ravandi F, Takahashi K, Daver N, Routbort M, et al. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. 2016;30:980\u20134.","journal-title":"Leukemia"},{"key":"1339_CR36","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/leu.2010.52","volume":"24","author":"O Kosmider","year":"2010","unstructured":"Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS\/myeloproliferative neoplasms. Leukemia. 2010;24:1094\u20136.","journal-title":"Leukemia"},{"key":"1339_CR37","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1158\/1078-0432.CCR-14-2203","volume":"21","author":"S-C Tsai","year":"2015","unstructured":"Tsai S-C, Shih L-Y, Liang S-T, Huang Y-J, Kuo M-C, Huang C-F, et al. Biological activities of RUNX1 mutants predict secondary acute leukemia transformation from chronic myelomonocytic leukemia and myelodysplastic syndromes. Clin Cancer Res. 2015;21:3541\u201351.","journal-title":"Clin Cancer Res"},{"key":"1339_CR38","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/ajh.27532","volume":"100","author":"J Wang","year":"2025","unstructured":"Wang J, Fang Z, Yang S, Yan K, Zhang J, Yu Y, et al. Venetoclax and hypomethylating agent in previously untreated higher-risk myelodysplastic syndromes and genotype signatures for response and prognosis: a real-world study. Am J Hematol. 2025;100:314\u20139.","journal-title":"Am J Hematol"},{"key":"1339_CR39","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1200\/JCO.2010.33.4938","volume":"29","author":"F Thol","year":"2011","unstructured":"Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol. 2011;29:2499\u2013506.","journal-title":"J Clin Oncol"},{"key":"1339_CR40","first-page":"2347","volume":"139","author":"T Grob","year":"2022","unstructured":"Grob T, Al Hinai AS, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood J Am Soc Hematol. 2022;139:2347\u201354.","journal-title":"Blood J Am Soc Hematol"},{"key":"1339_CR41","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1182\/blood.2024023840","volume":"144","author":"MJ Montoro","year":"2024","unstructured":"Montoro MJ, Palomo L, Haferlach C, Acha P, Chan O, Navarro V, et al. Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion. Blood. 2024;144:1722\u201331.","journal-title":"Blood"},{"key":"1339_CR42","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/ejh.13483","volume":"105","author":"J Deng","year":"2020","unstructured":"Deng J, Wu X, Ling Y, Liu X, Zheng X, Ye W, et al. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: a systematic review and meta-analysis. Eur J Haematol. 2020;105:524\u201339.","journal-title":"Eur J Haematol"},{"key":"1339_CR43","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549\u201356.","journal-title":"Nat Med"},{"key":"1339_CR44","doi-asserted-by":"crossref","unstructured":"Zhao Y, Chen W, Yu J, Pei S, Zhang Q, Shi J, et al. TP53 in MDS and AML: biological and clinical advances. Cancer Lett. 2024;588:216767.","DOI":"10.1016\/j.canlet.2024.216767"},{"key":"1339_CR45","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41375-023-01910-3","volume":"37","author":"LE Aguirre","year":"2023","unstructured":"Aguirre LE, Al Ali N, Sallman DA, Ball S, Jain AG, Chan O, et al. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes. Leukemia. 2023;37:1530\u20139.","journal-title":"Leukemia"},{"key":"1339_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217125","volume":"598","author":"Y Tang","year":"2024","unstructured":"Tang Y, Wang H, Zhang Z, Yao Y, Han Y, Wu D. DIAPH1 mutations predict a favorable outcome for de novo MDS. Cancer Lett. 2024;598:217125.","journal-title":"Cancer Lett"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01339-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01339-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01339-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T11:18:02Z","timestamp":1757330282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01339-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1339"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01339-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was supported by the General research fund, Research Grants Council, Hong Kong (HKU project code: 17118914); the Hong Kong Anti-Cancer Society Research Grant (HKU project code: AR190027); Celgene International II SARL (HKU project code: AR180044); the Ministry of Science and Technology, Taiwan (MOST 108-2628-B-002-015 and 111-2314-B-002-279), and the Ministry of Health and Welfare, Taiwan (MOHW 107-TDU-B-211-114009 and 111-TDU-B-221-114001). There are no other relevant competing interests to disclosed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}